Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?
Alpha-blocking drugs, although effective antihypertensive agents, often cause tachycardia, faintness and postural hypotension. Hybrid drugs such as labetalol, which has beta- as well as alpha-blocking action, ketanserin, which has 5-hydroxytryptamine (5HT)-blocking as well as alpha-blocking action, and urapidil, which appears to have a central effect as well as an alpha-blocking action, produce fewer side effects attributable to alpha-blockade. Urapidil appears to be an effective antihypertensive drug with a wide spectrum of action and few side effects.
Doyle
A E
AE
Department of Physiology, University of Melbourne, Parkville, Australia.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007650:Ketanserin / Q000627:therapeutic use; D007741:Labetalol / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010879:Piperazines; D007650:Ketanserin; C015568:urapidil; D007741:Labetalol